XML 14 R2.htm IDEA: XBRL DOCUMENT v3.25.3
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
ASSETS    
Cash and cash equivalents $ 18,998 $ 16,209
Marketable securities 0 15,036
Accounts receivable 502 900
Prepaid and other current assets 2,075 2,433
Total current assets 21,575 34,578
Property and equipment, net 22 72
Acquired license - intangible, net 139 192
Other assets 23 160
Total assets 21,759 35,002
Liabilities    
Accounts payable 619 1,284
Accrued liabilities 3,949 4,329
Total current liabilities 4,568 5,613
Other long-term liabilities 72 72
Total liabilities 4,640 5,685
Commitments and Contingencies (Note 14)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,756,686 and 8,409,582 shares at September 30, 2025 and December 31, 2024, respectively; and outstanding, 8,755,948 and 8,408,844 shares at September 30, 2025 and December 31, 2024, respectively 9 8
Additional paid-in capital 579,812 578,418
Treasury stock, at cost; 738 shares at September 30, 2025 and December 31, 2024 (708) (708)
Accumulated deficit (561,698) (548,066)
Accumulated other comprehensive loss (42) (81)
Total Lisata Therapeutics, Inc. stockholders' equity 17,373 29,571
Non-controlling interests (254) (254)
Total equity 17,119 29,317
Total liabilities, non-controlling interests and stockholders' equity $ 21,759 $ 35,002